Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 157201, 9 pages
http://dx.doi.org/10.1155/2015/157201
Review Article

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

1Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China
2Department of Preventive Medicine, College of Medicine, Shihezi University, Shihezi 832002, China
3Department of Physiology, Capital Medical University, Beijing 100069, China
4Department of Statistics, Graduate School of Arts and Sciences, Columbia University, New York, NY 10027, USA
5Department of Orthopedics, Tianjin Fifth Central Hospital, Tianjin 300450, China
6Shantou-Oxford Clinical Research Unit, Shantou University Medical College, Shantou 515041, China
7Department of Endocrinology and Metabolism, People’s Hospital, Peking University, Beijing 100044, China

Received 18 September 2014; Revised 12 December 2014; Accepted 22 December 2014

Academic Editor: Mitsuhiko Noda

Copyright © 2015 Feng Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Doyle and J. M. Egan, “Mechanisms of action of glucagon-like peptide 1 in the pancreas,” Pharmacology & Therapeutics, vol. 113, no. 3, pp. 546–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. S. Shyangdan, P. L. Royle, C. Clar, P. Sharma, and N. R. Waugh, “Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis,” BMC Endocrine Disorders, vol. 10, article 20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. S. Fineman, B. B. Cirincione, D. Maggs, and M. Diamant, “GLP-1 based therapies: differential effects on fasting and postprandial glucose,” Diabetes, Obesity and Metabolism, vol. 14, no. 8, pp. 675–688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Tzefos, K. Harris, and A. Brackett, “Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults,” Annals of Pharmacotherapy, vol. 46, no. 1, pp. 68–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Zinman, W. E. Schmidt, A. Moses, N. Lund, and S. Gough, “Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme,” Diabetes, Obesity & Metabolism, vol. 14, no. 1, pp. 77–82, 2012. View at Google Scholar
  8. D. Russell-Jones and R. Khan, “Insulin-associated weight gain in diabetes—causes, effects and coping strategies,” Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 799–812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Vergès, C. Bonnard, and E. Renard, “Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system,” Diabetes & Metabolism, vol. 37, no. 6, pp. 477–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. E. Kanoski, L. E. Rupprecht, S. M. Fortin, B. C. de Jonghe, and M. R. Hayes, “The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide,” Neuropharmacology, vol. 62, no. 5-6, pp. 1916–1927, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. E. Robinson, T. A. Holt, K. Rees, H. S. Randeva, and J. P. O'Hare, “Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis,” BMJ Open, vol. 3, no. 1, Article ID e001986, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Katout, H. Zhu, J. Rutsky et al., “Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression,” American Journal of Hypertension, vol. 27, no. 1, pp. 130–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Vilsbøll, M. Christensen, A. E. Junker, F. K. Knop, and L. L. Gluud, “Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials,” British Medical Journal, vol. 344, no. 7841, Article ID d7771, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. G. van Valkenhoef, G. Lu, B. de Brock, H. Hillege, A. E. Ades, and N. J. Welton, “Automating network meta-analysis,” Research Synthesis Methods, vol. 3, no. 4, pp. 285–299, 2012. View at Publisher · View at Google Scholar
  15. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Lu and A. E. Ades, “Combination of direct and indirect evidence in mixed treatment comparisons,” Statistics in Medicine, vol. 23, no. 20, pp. 3105–3124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. D. J. Spiegelhalter, N. G. Best, B. P. Carlin, and A. van der Linde, “Bayesian measures of model complexity and fit,” Journal of the Royal Statistical Society Series B: Statistical Methodology, vol. 64, no. 4, pp. 583–639, 2002. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  20. G. Salanti, A. E. Ades, and J. P. A. Ioannidis, “Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial,” Journal of Clinical Epidemiology, vol. 64, no. 2, pp. 163–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Chaimani, J. P. T. Higgins, D. Mavridis, P. Spyridonos, and G. Salanti, “Graphical tools for network meta-analysis in STATA,” PLoS ONE, vol. 8, no. 10, Article ID e76654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. A. Veroniki, H. S. Vasiliadis, J. P. Higgins, and G. Salanti, “Evaluation of inconsistency in networks of interventions,” International Journal of Epidemiology, vol. 42, no. 1, pp. 332–345, 2013. View at Publisher · View at Google Scholar
  23. J. B. Buse, M. Nauck, T. Forst et al., “Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study,” The Lancet, vol. 381, no. 9861, pp. 117–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. B. Buse, J. Rosenstock, G. Sesti et al., “Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6),” The Lancet, vol. 374, no. 9683, pp. 39–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. A. Maggio and F. X. Pi-Sunyer, “Obesity and type 2 diabetes,” Endocrinology Metabolism Clinics of North America, vol. 32, no. 4, pp. 805–822, 2003. View at Publisher · View at Google Scholar
  26. G. A. Bray, “Medical consequences of obesity,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2583–2589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S.-J. Shin, “Glucagon-like peptide-1 receptor agonists and their effects on weight reduction,” Journal of Diabetes Investigation, vol. 3, no. 6, pp. 490–491, 2012. View at Publisher · View at Google Scholar
  28. O. J. Phung, J. M. Scholle, M. Talwar, and C. I. Coleman, “Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes,” The Journal of the American Medical Association, vol. 303, no. 14, pp. 1410–1418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Niswender, X. Pi-Sunyer, J. Buse et al., “Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme,” Diabetes, Obesity and Metabolism, vol. 15, no. 1, pp. 42–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Marre, J. Shaw, M. Brändle et al., “Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU),” Diabetic Medicine, vol. 26, no. 3, pp. 268–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Zinman, J. Gerich, J. B. Buse et al., “Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD),” Diabetes Care, vol. 32, no. 7, pp. 1224–1230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Zinman, J. Gerich, J. B. Buse et al., “Erratum in ‘Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)’,” Diabetes Care, vol. 33, no. 3, p. 692, 2010. View at Google Scholar
  33. M. Nauck, A. Frid, K. Hermansen et al., “Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes,” Diabetes Care, vol. 32, no. 1, pp. 84–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. P. J. Larsen, “Mechanisms behind GLP-1 induced weight loss,” The British Journal of Diabetes & Vascular Disease, vol. 8, no. 2, supplement, pp. S34–S41, 2008. View at Publisher · View at Google Scholar
  35. B. McIntosh, C. Cameron, S. R. Singh et al., “Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis,” Open Medicine, vol. 5, no. 1, pp. e35–e48, 2011. View at Google Scholar · View at Scopus